Nisa Investment Advisors LLC Sells 315 Shares of Vericel Corporation (NASDAQ:VCEL)

Nisa Investment Advisors LLC decreased its holdings in Vericel Corporation (NASDAQ:VCEL) by 12.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,297 shares of the biotechnology company’s stock after selling 315 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Vericel were worth $102,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Principal Financial Group Inc. increased its stake in Vericel by 2.7% during the first quarter. Principal Financial Group Inc. now owns 270,154 shares of the biotechnology company’s stock worth $12,054,000 after acquiring an additional 7,222 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Vericel by 34.8% during the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 748 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Vericel in the fourth quarter valued at approximately $538,000. Zions Bancorporation N.A. grew its stake in Vericel by 19.8% during the 4th quarter. Zions Bancorporation N.A. now owns 38,186 shares of the biotechnology company’s stock worth $2,097,000 after buying an additional 6,307 shares during the last quarter. Finally, Swiss National Bank raised its stake in Vericel by 6.7% in the fourth quarter. Swiss National Bank now owns 96,500 shares of the biotechnology company’s stock valued at $5,299,000 after buying an additional 6,100 shares during the last quarter.

Analyst Upgrades and Downgrades

VCEL has been the topic of a number of research analyst reports. Stephens reissued an “overweight” rating and set a $67.00 price objective on shares of Vericel in a report on Monday, June 16th. Wall Street Zen lowered Vericel from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. Finally, Truist Financial dropped their price target on Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Vericel has a consensus rating of “Moderate Buy” and a consensus target price of $61.14.

Vericel Trading Down 2.5%

Shares of VCEL stock opened at $35.34 on Friday. The company’s 50-day moving average price is $41.54 and its 200-day moving average price is $46.90. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of 1,178.39 and a beta of 1.32. Vericel Corporation has a twelve month low of $35.18 and a twelve month high of $63.00.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.14). The business had revenue of $52.60 million during the quarter, compared to analysts’ expectations of $53.86 million. Vericel had a net margin of 1.25% and a return on equity of 1.09%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.08) EPS. As a group, equities research analysts predict that Vericel Corporation will post 0.14 EPS for the current year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.